All Updates

All Updates

icon
Filter
Partnerships
Cellectis signs investment agreement with AstraZeneca worth up to USD 245 million to develop next-gen therapeutics
Human Gene Editing
Nov 1, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Product updates
Partnerships
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Human Gene Editing

Human Gene Editing

Nov 1, 2023

Cellectis signs investment agreement with AstraZeneca worth up to USD 245 million to develop next-gen therapeutics

Partnerships

  • Gene editing biotech company Cellectis and AstraZeneca have partnered to accelerate the development of gene editing therapeutics, with a focus on oncology, immunology, and rare diseases.

  • Under the terms of the agreement, Cellectis will receive an initial payment of USD 105 million, including a USD 25 million upfront fee and USD 80 million in equity investment, resulting in a 22% stake in Cellectis. An additional USD 140 million equity investment by AstraZeneca is expected in early 2024, which will result in a 44% stake in Cellectis.

  • The partnership will leverage Cellectis' gene editing technologies and manufacturing capabilities to create novel treatments across 25 exclusive genetic targets, which could result in up to 10 potential products for development. These products may also be eligible for an option fee for an investigational new drug and milestone payments, ranging from USD 70 million to USD 220 million for each candidate, based on progress in development, regulatory approval, and sales. The partnership also aims at expanding AstraZeneca's cell therapy offerings for cancer and advancing genomic medicines for rare diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.